Phreesia Faces Securities Fraud Lawsuit
Analysis based on 8 articles · First reported May 15, 2026 · Last updated May 16, 2026
The market is impacted by the significant drop in Phreesia's stock price following its reduced revenue growth projections, leading to a class action lawsuit. This event highlights the risks associated with companies failing to meet guidance and the potential for legal repercussions.
Pomerantz LLP has filed a class action lawsuit against Phreesia, a publicly traded company, alleging securities fraud and unlawful business practices. This legal action follows Phreesia's announcement on March 30, 2026, of significantly reduced revenue growth projections for fiscal year 2027, attributing the shortfall to macroeconomic factors and weaker pharmaceutical marketing commitments. Following this news, Phreesia's stock price plummeted by 26.56% on March 31, 2026. Investors who purchased Phreesia securities during the Class Period have until July 13, 2026, to seek appointment as Lead Plaintiff.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard